Nyrada (ASX:NYR) ROE % Adjusted to Book Value: -3.39% (As of Dec. 2025)


ASX:NYR Nyrada Inc ASX:NYR
38 GF Score
Price A$0.44
! 1 Warning Sign
View Full Analysis

What is Nyrada ROE % Adjusted to Book Value?

Nyrada ASX:NYR 38 ROE % Adjusted to Book Value is -3.39% as of Dec. 2025. GuruFocus rates ASX:NYR with a GF Score™ of 38/100. The stock has 1 warning sign investors should review.

Nyrada's ROE % for the quarter that ended in Dec. 2025 was -94.99%. Nyrada's PB Ratio for the quarter that ended in Dec. 2025 was 28.00. Nyrada's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -3.39%.

Nyrada ROE % Adjusted to Book Value Related Terms

Nyrada ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Nyrada's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nyrada ROE % Adjusted to Book Value Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -10.28 -16.74 -94.98 -14.16 -7.95

Nyrada Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.11 -30.08 -26.80 -7.17 -3.39

ASX:NYR vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Nyrada's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyrada ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Nyrada's ROE % Adjusted to Book Value falls into.


ASX:NYR
38GF Score
Nyrada Inc ASX:NYR
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nyrada ROE % Adjusted to Book Value Calculation

Nyrada's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-112.32% / 14.12
=-7.95%

Nyrada's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-94.99% / 28.00
=-3.39%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -3.39% mean?
Nyrada (ASX:NYR) has a ROE % Adjusted to Book Value of -3.39% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Nyrada and its competitors.
Is Nyrada's ROE % Adjusted to Book Value too high?
Nyrada's current ROE % Adjusted to Book Value is -3.39%. Overall, Nyrada has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Nyrada's ROE % Adjusted to Book Value compare to VRTX and REGN?
Nyrada's ROE % Adjusted to Book Value of -3.39% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Nyrada and its competitors. Nyrada's current ROE % Adjusted to Book Value is -3.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyrada stock overvalued right now?
Nyrada (ASX:NYR) has a current ROE % Adjusted to Book Value of -3.39%. The current ROE % Adjusted to Book Value is -3.39%. Nyrada's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Nyrada (ASX:NYR), the current ROE % Adjusted to Book Value is -3.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nyrada Business Description

Address 180 George Street, Sydney Place, Level 22/23, Salesforce Tower, Sydney, NSW, AUS, 2000
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
38GF Score

Get the complete analysis for ASX:NYR

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.44
Price